<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.163404.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Study Protocol</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Protocol of Peripheral Artery Disease Screening: The Phase -1 of the Global Artery Project (GAP)</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: awaiting peer review]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Meneas</surname>
                        <given-names>Christophe</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Funding Acquisition</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-4793-4850</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Sall</surname>
                        <given-names>Fatouma</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Dere</surname>
                        <given-names>Luc</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Manhan</surname>
                        <given-names>Noel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Abro</surname>
                        <given-names>Samuel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Binate</surname>
                        <given-names>Alassane</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>N'Guessan</surname>
                        <given-names>Ismael</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>M'Bra</surname>
                        <given-names>Innocent</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-6521-2296</uri>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Assere</surname>
                        <given-names>Arnaud</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-9510-6649</uri>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Acho</surname>
                        <given-names>Kevun</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kee</surname>
                        <given-names>Cedric</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a6">6</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kone</surname>
                        <given-names>Salifou</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a7">7</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kouassi</surname>
                        <given-names>Lauret</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a7">7</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Gnazegbo</surname>
                        <given-names>Any</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a8">8</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Koffi</surname>
                        <given-names>Reine</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a9">9</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Gonan</surname>
                        <given-names>Yannick</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a9">9</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Pkan</surname>
                        <given-names>Jonathan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a9">9</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kouakou</surname>
                        <given-names>Bernadin</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a10">10</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Karidioula</surname>
                        <given-names>Emilie</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a11">11</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Dido</surname>
                        <given-names>Joseph Arnauld</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a11">11</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Teh</surname>
                        <given-names>Kassi Stephane</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a11">11</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Edoukou</surname>
                        <given-names>Jacques Nelson</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a11">11</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Cardiovascular and Thoracic Surgery Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a2">
                    <label>2</label>Cardiology Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a3">
                    <label>3</label>Biochemistry Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a4">
                    <label>4</label>Orthopedic and Trauma Surgery Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a5">
                    <label>5</label>Endocrinology Unit of Internal Medicine Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a6">
                    <label>6</label>Pharmacology Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a7">
                    <label>7</label>Internal Medicine Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a8">
                    <label>8</label>Neurology Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a9">
                    <label>9</label>Nephrology Department, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a10">
                    <label>10</label>General and Visceral Surgery, Alassane Ouattara University Medical Sciences Training and Research Unit Bouake Teaching Hospital, Bouake, Vall&#x00e9;e du Bandama District, Cote d'Ivoire</aff>
                <aff id="a11">
                    <label>11</label>General Medicine, Ministry of Health, Public Hygiene and Universal Health Coverage, Bouake, Cote d'Ivoire</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:cmeneas5@gmail.com">cmeneas5@gmail.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>24</day>
                <month>9</month>
                <year>2025</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2025</year>
            </pub-date>
            <volume>14</volume>
            <elocation-id>976</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>17</day>
                    <month>9</month>
                    <year>2025</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Meneas C et al.</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/14-976/pdf"/>
            <abstract>
                <title>Abstract*</title>
                <p>The Global Artery Project (GAP) launched by the Institute of Continuing Medical Education (ICME) in Cote d&#x2019;Ivoire, a West African country aims to fill the gap between needs and contributions in the knowledge, diagnosis, and management of acquired degenerative arterial diseases. This project will have a progressive implementation in three phases and will focus on the main arterial diseases caused by atherosclerosis and mediacalcosis. It will concern Peripheral Artery Diseases, Coronary Artery Diseases and Carotid Artery Stenosis. Thus, we will have Phase -1 dedicated to Peripheral Artery Diseases (PAD), Phase -2 dedicated to Coronary Artery Diseases (CAD), and Phase -3 dedicated to Carotid Artery Stenosis (CAS). This protocol is related to Phase-1 and aims to set out objectives by explaining the actions to be taken, the rationale, and the tactics of these objectives.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Artery</kwd>
                <kwd>Disease</kwd>
                <kwd>Screening</kwd>
                <kwd>Global Artery Project.</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>In 2015, the prevalence of Peripheral Artery Disease (PAD) was 237 million cases worldwide, with a relative increase of 17% compared to 2010.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> The prevalence seems to be booming in low- and middle-income countries, with a 22.6% relative increase, vs. 4.5% in high-income countries.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>,
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> In addition to its high prevalence, PAD multiplies by 4 the 10-year cardiovascular mortality in men (18.7% versus 4.4%) and multiplies by 3 the 10-year cardiovascular mortality in women (12.6% versus 4.1%).
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> Mortality rates for asymptomatic PAD are similar to those for intermittent claudication and have remained unchanged over the last three decades.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>,
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> The main underlying causes of lower-limb PAD are smoking, diabetes, high blood pressure, and elevated blood fat (cholesterol) levels.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> Diabetes is a major risk factor for PAD with multiple and serious complications. Diabetic foot is undoubtedly one of the most feared complications in diabetic patients because it exposes them to the risk of amputation, which is experienced by patients as a social drama that can lead to despair, depression, anxiety, loss of self-esteem, stigmatization, isolation, and a real feeling of bodily disintegration.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> PAD represents more than 88% of the causes of diabetic foot, with an amputation rate of more than 26% in our country.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> Sensitive to this public health problem, the Institute of Continuing Medical Education (ICME) LLC, specialized in health promotion, is launching a Phase 1 of the &#x201c;Global Artery Project
                <sup>&#x00ae;</sup>&#x201d; focused on the Peripheral Artery Disease. To define the objectives of Phase 1 of this project, we were inspired by the 2024 multisociety guidelines for the management of lower extremity decline in the (PAD) National Action Plan.
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>,
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> Thus, we retained six objectives.</p>
            <p>

                <bold>Objective 1:</bold> To improve at-risk population awareness of PAD symptoms and diagnostic tools across the national territory.</p>
            <p>

                <bold>Objective 2:</bold> Organization of the Continuing Medical Education for the National PAD Team.</p>
            <p>

                <bold>Objective 3:</bold> Activate health care systems and development partners to provide PAD Screening programs.</p>
            <p>

                <bold>Objective 4:</bold> Reduce the rates of non-traumatic lower extremity amputations related to PAD through lower extremity revascularization strategic plans (drugs, open surgery, Stent, Vascular Rehabilitation).</p>
            <p>

                <bold>Objective 5:</bold> To increase and sustain research in order to better understand the prevention, diagnosis, and treatment of PAD.</p>
            <p>

                <bold>Objective 6:</bold> Provide national and regional health policy decision-makers with a national and regional database based on an AOMI register and scientific publications.</p>
            <p>This protocol will be dedicated to Objectives 1, 2, and 3. Objectives 4, 5, and 6 will be the subject of another protocol study.</p>
        </sec>
        <sec id="sec2">
            <title>Protocol</title>
            <p>

                <bold>OBJECTIVE 1:</bold> Improve At-Risk Population Awareness of PAD Symptoms and Diagnosis Tools across national territory.</p>
            <p>To achieve this goal, we plan 3 actions:
                <list list-type="bullet">
                    <list-item>
                        <label>-</label>
                        <p>Across the national territory, carry out at-risk groups&#x2019; awareness on the &#x201c;prevention of diabetic feet&#x201d; and explain the link between diabetic feet and PAD.</p>
                    </list-item>
                    <list-item>
                        <label>-</label>
                        <p>Across the national territory, carry out PAD screening in at-risk groups during awareness days.</p>
                    </list-item>
                    <list-item>
                        <label>-</label>
                        <p>Secure funding to launch and sustain PAD awareness and screening initiatives.</p>
                    </list-item>
                </list>
            </p>
            <p>

                <bold>Action 1.1: Across the national territory, carry out at-risk groups&#x2019; awareness on the &#x201c;prevention of diabetic feet&#x201d; and explain the link between diabetic feet and PAD</bold>
            </p>
            <p>

                <bold>

                    <italic toggle="yes">Rationale:</italic>
</bold> Diabetic foot is a complication of PAD that is known and feared by patients in general; PAD itself is unknown to the population. Given the non-existence of a priority region and given limited resources and for reasons of efficiency, awareness will focus on the main regions of our country and will prioritize the at-risk groups as defined in current guidelines
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>,
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>: age &#x2265;65 years, Age 50-64 y, with risk factors for atherosclerosis (e.g., diabetes, history of smoking, dyslipidemia, hypertension), chronic kidney disease, or family history of PAD, Age &lt;50 years, with diabetes, and one additional risk factor for atherosclerosis.</p>
            <p>

                <bold>

                    <italic toggle="yes">Tactics:</italic>
</bold>
            </p>
            <p>

                <bold>1.1A:</bold> Identify the 10 major cities in the main regions of our country, which are poles of concentration of the population to reach the maximum number of people and a representative portion of the national population (
                <xref ref-type="fig" rid="f1">
Figure 1</xref>).</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>
Figure 1. </label>
                <caption>
                    <title>Main Cities selected (red dots) for awareness and PAD screening days in public squares and public hospitals in Cote d'Ivoire.</title>
                    <p>PAD: Peripheral Arterial Disease.</p>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/179747/cb6c094f-4666-45f3-99cf-34893b936992_figure1.gif"/>
            </fig>
            <p>

                <bold>1.1B:</bold> Organize two teams (Team A and Team B) of awareness and screening.</p>
            <p>

                <bold>1.1C:</bold> Set up a local committee composed of local facilitators such as the regional chief physician, a representative of the town hall, a representative of traditional leaders, and a representative of religious leaders.</p>
            <p>

                <bold>1.1D:</bold> Develop advertising and awareness posters on prevention of &#x201c;diabetic feet&#x201d; specifying the population at risk.</p>
            <p>

                <bold>1.1E:</bold> Develop a communication plan on prevention of &#x201c;diabetic feet&#x201d; and its link with PAD via local radio stations, local religious worship, town hall information channels, and the organization of traditional communities.</p>
            <p>

                <bold>Action 1.2: Across the national territory, carry out at-risk groups&#x2019; PAD screening during awareness days</bold>
            </p>
            <p>

                <bold>

                    <italic toggle="yes">Rationale:</italic>
</bold> For reasons of inclusion and efficiency, PAD screening will focus on the main regions of our country and will prioritize the at-risk groups for messaging and screening as defined in the current guidelines
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>,
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>: age &#x2265;65 years, Age 50-64 y, with risk factors for atherosclerosis (e.g., diabetes, history of smoking, dyslipidemia, hypertension), chronic kidney disease, or family history of PAD, Age &lt;50 years, with diabetes, and one additional risk factor for atherosclerosis.</p>
            <p>

                <bold>

                    <italic toggle="yes">Tactics:</italic>
</bold>
            </p>
            <p>

                <bold>1.2A:</bold> For PAD screening, use the same 10 major cities of the main regions Identified for awareness on prevention of &#x201c;diabetic feet.&#x201d;</p>
            <p>

                <bold>1.2B:</bold> Take advantage of awareness days to achieve the PAD screening.</p>
            <p>

                <bold>1.2C:</bold> Set up PAD screening stands at public awareness sites.</p>
            <p>

                <bold>1.2D:</bold> Carry out the screening for PAD by automatic measurement of Ankle Brachial Index in subjects at risk of PAD.</p>
            <p>

                <bold>1.2E:</bold> Collect screening data on a survey sheet.</p>
            <p>

                <bold>Action 1.3: Secure funding to launch and sustain PAD awareness and screening initiatives</bold>
            </p>
            <p>

                <bold>

                    <italic toggle="yes">Rationale:</italic>
</bold> Communication through consistent messaging on a national scale requires significant funding. However, in low- and middle-income countries (LMIC), the financial resources of the population are limited.</p>
            <p>

                <bold>

                    <italic toggle="yes">Tactics:</italic>
</bold>
            </p>
            <p>

                <bold>1.3A:</bold> Identify needs and assess their financial costs for both awareness raising and screening.</p>
            <p>

                <bold>1.3B:</bold> Identify funders to discuss opportunities.</p>
            <p>

                <bold>1.3C:</bold> Send letters requesting financial support from potential funders.</p>
            <p>

                <bold>OBJECTIVE 2:</bold> Organization of the Continuing Medical Education for the National PAD Team.</p>
            <p>To achieve this goal, a main action must be taken:</p>
            <p>

                <bold>Action:</bold> Establish a National PAD Team made up of 176 members including 3 vascular physicians, 2 diabetologists, 2 radiologists, 2 biochemists, 2 orthopedic surgeons, 4 vascular surgeons, 10 patients, 50 nurses (5 nurses &#x00d7; 10 regions), 1 podiatrist, and 100 general practitioners (10 general practitioners &#x00d7; 10 regions).</p>
            <p>Using CME, raise awareness among the PAD Team about the extent of the PAD problem, and explain to them the risk factors and diagnostic and management methods of PAD.</p>
            <p>

                <bold>

                    <italic toggle="yes">Rationale:</italic>
</bold> Despite its prevalence and serious complications that can lead to amputation or patient death, PAD is under-recognized by clinicians due to major gaps in their knowledge and understanding of the risk factors, screening, diagnosis, and management methods of PAD. The Global Artery Project (GAP) aims to fill these gaps.</p>
            <p>

                <bold>

                    <italic toggle="yes">Tactics:</italic>
</bold>
            </p>
            <p>

                <bold>2.A:</bold> Establish a national PAD Team.</p>
            <p>

                <bold>2.B:</bold> Organize PAD Team CME.</p>
            <p>

                <bold>2.C:</bold> Present during the CME, the worldwide, African and Ivorian prevalence of PAD, the risk factors of PAD and their management methods.</p>
            <p>

                <bold>2.D:</bold> Present during the CME, the diagnostic and screening methods of PAD.</p>
            <p>

                <bold>2.E:</bold> Explain during the CME, the pharmacological, surgical, interventional and functional methods of managing PAD.</p>
            <p>

                <bold>OBJECTIVE 3:</bold> Activate health care systems and development partners to provide PAD Screening programs.</p>
            <p>The goal s to screen 500 people per screening site for a total of 5,000 people across the 10 screening sites. To minimize screening program costs, 
                <bold>we plan to form two teams (Team A and Team B)</bold> that will travel to five screening sites for a total of 2,500 people screened per team. These screenings will be performed during the awareness days.</p>
            <p>To achieve this goal, a main action must be taken:</p>
            <p>

                <bold>Action:</bold> Free Screening of Peripheral Arterial Disease (PAD) by measuring the Ankle-Brachial Pressure Index (ABI) in at-risk patients.</p>
            <p>

                <bold>

                    <italic toggle="yes">Rationale:</italic>
</bold> A pilot study conducted from January 2022 to March 2024 screened 474 diabetic patients, including 211 (44.5%) men and 263 (55.5%) women with a mean age of 59.84 &#x00b1; 12 years [range: 18-91 years]. The prevalence of PAD was 15.8% (N = 75). Patients who screened positive and carried PAD were managed in a specialized environment with pharmacological medical treatment, a vascular rehabilitation program, and arterial revascularization surgery, if necessary. This specialized medical monitoring has allowed us to obtain excellent immediate results, allowing the foot to be saved and the absence of amputation in nearly 90% of cases. Considering these results, we wish to extend this screening campaign to more at-risk groups as defined in the current guidelines
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>,
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>: age &#x2265;65 years, Age 50-64 y, with risk factors for atherosclerosis (e.g., diabetes, history of smoking, dyslipidemia, hypertension), chronic kidney disease, or family history of PAD, Age &lt;50 years, with diabetes, and one additional risk factor for atherosclerosis. The cost of the measurement was a limiting factor that prevented a large number of people from accessing this screening. To extend this screening to more people, 
                <bold>the FREE measurement of the Brachial Pressure Index (ABI)</bold> could be an interesting solution, which requires funders to bear the costs of this screening.</p>
            <p>

                <bold>

                    <italic toggle="yes">Tactics:</italic>
</bold>
            </p>
            <p>

                <bold>3.A:</bold> Identify needs and assess their financial costs for PAD screening during awareness days.</p>
            <p>

                <bold>3.B:</bold> Doing PAD screening devices during awareness days.</p>
            <p>

                <bold>3.C:</bold> Identify funders to discuss opportunities.</p>
            <p>

                <bold>3.D:</bold> Send letters requesting financial support from funders for the PAD screening program.</p>
            <sec id="sec3">
                <title>Consent statement</title>
                <p>Verbal consent will be chosen because it is the consent which is used in our local institution regarding disease screening or physician training. It will be a voluntary screening or training after preview information period. Also, this study will not use any potentially invasive or potentially dangerous tools for participants and will protect all personal data.</p>
            </sec>
            <sec id="sec4">
                <title>Dissemination</title>
                <p>We will use academic media (i.e., peer-reviewed journal articles and national and international conference presentations) to disseminate the findings of the study.</p>
            </sec>
            <sec id="sec5">
                <title>Study status</title>
                <p>We began the pilot study.</p>
            </sec>
        </sec>
        <sec id="sec6" sec-type="discussion">
            <title>Discussion</title>
        </sec>
        <sec id="sec7">
            <title>Ethical considerations</title>
            <p>The Ethic Committee of Bouake Teaching Hospital for Medical Care and Scientific Research gave us the institutional approval 
                <bold>(N&#x00b0; 01 MSHP/CHU-B/DMS/CARDIO/K.C/22)</bold>.</p>
        </sec>
    </body>
    <back>
        <sec id="sec10" sec-type="data-availability">
            <title>Data availability</title>
            <p>No underlying data are associated with this article.</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Song</surname>
                            <given-names>P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rudan</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhu</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.</article-title>
                    <source>

                        <italic toggle="yes">Lancet Glob. Health.</italic>
</source>
                    <year>2019</year>;<volume>7</volume>:<fpage>e1020</fpage>&#x2013;<lpage>e1030</lpage>.
                    <pub-id pub-id-type="pmid">31303293</pub-id>
                    <pub-id pub-id-type="doi">10.1016/S2214-109X(19)30255-4</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>Q</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>Q</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review.</article-title>
                    <source>

                        <italic toggle="yes">BMC Cardiovasc. Disord.</italic>
</source>
                    <year>2019</year>;<volume>19</volume>:<fpage>17</fpage>.
                    <pub-id pub-id-type="pmid">30646843</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s12872-018-0960-8</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6332557</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <collab>Ankle Brachial Index Collaboration</collab>

                        <name name-style="western">
                            <surname>Fowkes</surname>
                            <given-names>FG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Murray</surname>
                            <given-names>GD</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.</article-title>
                    <source>

                        <italic toggle="yes">JAMA.</italic>
</source>
                    <year>2008</year>;<volume>300</volume>:<fpage>197</fpage>&#x2013;<lpage>208</lpage>.
                    <pub-id pub-id-type="doi">10.1001/jama.300.2.197</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sartipy</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sigvant</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lundin</surname>
                            <given-names>F</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Ten-year mortality in different peripheral arterial disease stages: a population-based observational study on outcome.</article-title>
                    <source>

                        <italic toggle="yes">Eur. J. Vasc. Endovasc. Surg.</italic>
</source>
                    <year>2018</year>;<volume>55</volume>:<fpage>529</fpage>&#x2013;<lpage>536</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.ejvs.2018.01.019</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Criqui</surname>
                            <given-names>MH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Langer</surname>
                            <given-names>RD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fronek</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Mortality over a period of 10 years in patients with peripheral arterial disease.</article-title>
                    <source>

                        <italic toggle="yes">N. Engl. J. Med.</italic>
</source>
                    <year>1992</year>;<volume>326</volume>:<fpage>381</fpage>&#x2013;<lpage>386</lpage>.
                    <pub-id pub-id-type="pmid">1729621</pub-id>
                    <pub-id pub-id-type="doi">10.1056/NEJM199202063260605</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Nordanstig</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Behrendt</surname>
                            <given-names>CA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Baumgartner</surname>
                            <given-names>I</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Editor&#x2019;s Choice -- European Society for Vascular Surgery (ESVS): 2024 Clinical practice guidelines on the management of asymptomatic lower-limb peripheral arterial disease and intermittent claudication.</article-title>
                    <source>

                        <italic toggle="yes">Eur. J. Vasc. Endovasc. Surg.</italic>
</source>
                    <year>2024</year>;<volume>67</volume>:<fpage>9</fpage>&#x2013;<lpage>96</lpage>.
                    <pub-id pub-id-type="pmid">37949800</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ejvs.2023.08.067</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Cunha</surname>
                            <given-names>BM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bazanelli</surname>
                            <given-names>PH</given-names>
                        </name>
</person-group>:
                    <article-title>Emotional aspects present in the lives of amputees: a literature review.</article-title>
                    <source>

                        <italic toggle="yes">Psicologia: teoria e pr&#x00e1;tica. </italic>
</source>
                    <volume>20</volume>:<fpage>47</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Dago</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Danho</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yao</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Le Pied Diab&#x00e9;tique en C&#x00f4;te d&#x2019;Ivoire: Exp&#x00e9;rience du Service d&#x2019;Endocrinologie Diab&#x00e9;tologie du CHU de Yopougon.</article-title>
                    <source>

                        <italic toggle="yes">Health Sci. Dis.</italic>
</source>
                    <year>2020</year>;<volume>21</volume>.
                    <ext-link ext-link-type="uri" xlink:href="https://www.hsd-fmsb.org/index.php/hsd/article/view/1572">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="other">
                    <collab>American Heart Association</collab>:
                    <article-title>Peripheral Artery Disease National Action Plan. </article-title>Accessed November 23, 2024.
                    <ext-link ext-link-type="uri" xlink:href="https://www.heart.org/en/health-topics/peripheral-artery-disease/pad-resources/pad-action-plan">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="other">
                    <collab>American College of Cardiology</collab>:
                    <article-title>The Six Strategic Goals of the PAD National Action Plan. </article-title>Accessed November 23, 2024.
                    <ext-link ext-link-type="uri" xlink:href="https://www.acc.org/latest-in-cardiology/articles/2024/11/18/11/31/the-six-strategic-goals-of-the-pad-national-action-plan#:~:text=The%20PAD%20National%20Action%20Plan%20outlines%20six%20strategic%20goals%20aimed,the%20PAD%20National%20Action%20Plan">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Gornik</surname>
                            <given-names>HL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Aronow</surname>
                            <given-names>HD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Goodney</surname>
                            <given-names>PP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guidelines for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
                    <source>

                        <italic toggle="yes">Circulation.</italic>
</source>
                    <year>2024</year>;<volume>149</volume>:<fpage>e1313</fpage>&#x2013;<lpage>e1410</lpage>.
                    <pub-id pub-id-type="doi">10.1161/CIR.0000000000001251</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>
